Physician profile
Celia Liang
NPI 1396994018
$8,807.91
in general payments reported to CMS, 2019-2025
21 companies · $1,226 in 2025
The $1,226 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $448 · 2021: $997 · 2022: $1,172 · 2023: $1,376 · 2024: $2,121 · 2025: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,722.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,443.83 | 2019-2025 | Repatha, Evenity, Repatha |
| Gilead Sciences, INC. | $2,405.35 | 2019-2025 | Vemlidy |
| Novo Nordisk INC | $852.10 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $712.45 | 2021-2025 | |
| Amarin Pharma, INC. | $567.06 | 2019-2022 | |
| Lilly USA, LLC | $566.16 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.78 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $262.50 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $173.28 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $114.50 | 2022-2023 | |
| Pfizer INC. | $67.14 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.87 | 2019-2020 | |
| Allergan, INC. | $52.70 | 2019 | |
| Esperion Therapeutics, INC. | $38.37 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.76 | 2023 | Arexvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.31 | 2023 | |
| Calliditas Therapeutics US INC. | $22.51 | 2025 | Tarpeyo |
| Regeneron Healthcare Solutions, INC. | $21.50 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $19.77 | 2025 | Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $17.50 | 2022 | |
| Horizon Therapeutics Plc | $15.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.